SEARCH:   Advanced

Blood, 1 July 2006, Vol. 108, No. 1, pp. 45-51. Prepublished online as a Blood First Edition Paper on January 10, 2006; DOI 10.1182/blood-2005-08-3294. This Article Full Text (PDF) All Versions of this Article: 2005-08-3294v1 108/1/45    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Faderl, S. Articles by Kantarjian, H. M Search for Related Content PubMed PubMed Citation Articles by Faderl, S. Articles by Kantarjian, H. M Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted August 15, 2005 Accepted December 19, 2005 Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years Stefan Faderl*, Srdan Verstovsek, Jorge Cortes, Farhad Ravandi, Miloslav Beran, Guillermo Garcia-Manero, Alessandra Ferrajoli, Zeev Estrov, Susan O'Brien, Charles Koller, Francis J Giles, William Wierda, Monica Kwari, and Hagop M Kantarjian Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA * Corresponding author; email: sfaderl{at}mdanderson.org. Outcome of patients with acute myeloid leukemia (AML) over age 60 remains unsatisfactory with low remission rates and poor overall survival. We have previously established the activity of clofarabine plus cytarabine in AML relapse. We now conducted a phase 2 study of clofarabine plus cytarabine in patients 50 years with previously untreated AML. Clofarabine was given at 40mg/m2 as a 1-hour intravenous infusion for 5 days (days 2 to 6) followed 4 hours later by cytarabine at 1g/m2/day as a 2-hour intravenous infusion for 5 days (days 1 to 5). Of 60 patients, 29 (48%) had secondary AML, 30 (50%) had abnormal karyotypes (monosomy 5 and/or 7 in 15 [25%]), and 11 (21%) showed Flt3 abnormalities. The overall response rate (OR) was 60% (52% CR, 8% CRp). Four patients (7%) died during induction. Adverse events were mainly grade 2 and included diarrhea, nausea/vomiting, mucositis, skin reactions, liver test abnormalities, and infusion-related facial flushing and headaches. Myelosuppression was common. Clofarabine plus cytarabine has activity in adult AML achieving a good CR rate. However, survival does not appear to be improved compared to other regimens. Modifications of this combination in AML therapy of older patients warrant further evaluation. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. Prebet, N. Boissel, S. Reutenauer, X. Thomas, J. Delaunay, J.-Y. Cahn, A. Pigneux, B. Quesnel, F. Witz, S. Thepot, et al. Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup J. Clin. Oncol., October 1, 2009; 27(28): 4747 - 4753. [Abstract] [Full Text] [PDF] S. Jeha, B. Razzouk, M. Rytting, S. Rheingold, E. Albano, R. Kadota, L. Luchtman-Jones, L. Bomgaars, P. Gaynon, S. Goldman, et al. Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia J. Clin. Oncol., September 10, 2009; 27(26): 4392 - 4397. [Abstract] [Full Text] [PDF] H. D. Klepin and L. Balducci Acute Myelogenous Leukemia in Older Adults Oncologist, March 1, 2009; 14(3): 222 - 232. [Abstract] [Full Text] [PDF] G. J. Roboz Treatment of Elderly Patients with Acute Myeloid Leukemia: Lowering the Intensity ASCO Educational Book, January 1, 2009; 2009(1): 378 - 383. [Abstract] [Full Text] [PDF] P. S. Becker, E. Estey, S. Petersdorf, P. C. Hendrie, J. M. Pagel, D. Stirewalt, A. Shustov, B. E. Storer, and F. R. Appelbaum Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 2964 - 2964. [Abstract] J. Laubach and A. V. Rao Current and Emerging Strategies for the Management of Acute Myeloid Leukemia in the Elderly Oncologist, October 1, 2008; 13(10): 1097 - 1108. [Abstract] [Full Text] [PDF] S. Berentsen Rituximab for the treatment of autoimmune cytopenias Haematologica, December 1, 2007; 92(12): 1589 - 1596. [Full Text] [PDF] E. Atallah, J. Cortes, S. O'Brien, S. Pierce, M. B. Rios, E. Estey, M. Markman, M. Keating, E. J. Freireich, and H. Kantarjian Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia Blood, November 15, 2007; 110(10): 3547 - 3551. [Abstract] [Full Text] [PDF] J. E. Karp, R. M. Ricklis, K. Balakrishnan, J. Briel, J. Greer, S. D. Gore, B. D. Smith, M. A. McDevitt, H. Carraway, M. J. Levis, et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias Blood, September 15, 2007; 110(6): 1762 - 1769. [Abstract] [Full Text] [PDF] H. P. Erba Prognostic Factors in Elderly Patients with AML and the Implications for Treatment Hematology, January 1, 2007; 2007(1): 420 - 428. [Abstract] [Full Text] [PDF] W. Stock Controversies in Treatment of AML: Case-based Discussion Hematology, January 1, 2006; 2006(1): 185 - 191. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020